AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31978740 — intervention group
Group type: COMPARATOR
Intervention: Limited knowledge of mothers about diarrhea
Number of subjects: 826
Study 31978740 — intervention group
Group type: COMPARATOR
Intervention: Absence of hand washing among mothers/caregivers at critical times
Number of subjects: 826
Study 31978740 — intervention group
Group type: COMPARATOR
Intervention: Sharing residence with domestic animals
Number of subjects: 826
Study 31978740 — intervention group
Group type: COMPARATOR
Intervention: Living in semi pastoral areas
Number of subjects: 826
Study 31978740 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated children for rotavirus prevention
Number of subjects: 826
Study 31978740 — intervention group
Group type: COMPARATOR
Intervention: Households obtaining water from unimproved sources
Number of subjects: 826
Study 31978740 — intervention group
Group type: COMPARATOR
Intervention: Households with unimproved latrine facilities
Number of subjects: 826
Study 29306452 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline polyunsaturated phosphatidylcholines (PC)/lysoPC/PC‐plasmalogens and polyunsaturated cholesterol esters (CE)
Number of subjects: 983
Study 29306452 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline monoacylglycerols (MAGs)/diacylglycerols (DAGs) and short triacylglycerols (TAGs)
Number of subjects: 983
Study 29306452 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline phosphatidylethanolamines (PEs) and their 1‐y changes
Number of subjects: 983
Study 29306452 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean Diet intervention
Number of subjects: 983
Study 27566742 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort 0.9 mg/kg/d
Number of subjects: 196
Study 27566742 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort 1.2 mg/kg/d
Number of subjects: 196
Study 27566742 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 0.75 mg/kg/d
Number of subjects: 196
Study 27566742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 23925646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal 0.25% bupivacaine (100 mg)
Number of subjects: 104
Study 23925646 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal saline
Number of subjects: 104
Study 23893225 — intervention group
Group type: EXPERIMENTAL
Intervention: Active and passive warming measures as described in ASPAN's guidelines
Number of subjects: 60
Study 23893225 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 60
Study 20497992 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham risk equation
Number of subjects: 0
Study 20497992 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocock risk equation
Number of subjects: 0
Study 20497992 — intervention group
Group type: EXPERIMENTAL
Intervention: Dubbo risk equation
Number of subjects: 0
Study 20497992 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk equations
Number of subjects: 0
Study 20497992 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalibration analysis
Number of subjects: 0
Study 18701233 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bedded rooms
Number of subjects: 2
Study 18701233 — intervention group
Group type: COMPARATOR
Intervention: Four-bedded rooms
Number of subjects: 2
Study 16870658 — intervention group
Group type: EXPERIMENTAL
Intervention: OrM3 0.5, 2, 3 or 4 mg orally once daily
Number of subjects: 412
Study 16870658 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide 36 mug by inhalation four times daily
Number of subjects: 412
Study 16870658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 12882874 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICKI
Number of subjects: 150
Study 12882874 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/HOMA-IR
Number of subjects: 150
Study 12882874 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICKI or 1/HOMA-IR
Number of subjects: 150
Study 10791670 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nail insertion
Number of subjects: 94
Study 10791670 — intervention group
Group type: COMPARATOR
Intervention: Unreamed intramedullary nail insertion
Number of subjects: 94
Study 8851905 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (18.5% w/v solution)
Number of subjects: 9
Study 8851905 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize syrup solids (18.5% w/v solution)
Number of subjects: 9
Study 8851905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (18.5% w/v solution)
Number of subjects: 9
Study 1632399 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy (atenolol, dihydroergotamine, domperidone, cafedrine, elastic compression stockings)
Number of subjects: 30
Study 1632399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1632399 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and placebo)
Number of subjects: 30
Study 6760390 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of sobrerol for 14 days
Number of subjects: 23
Study 6760390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6760390 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g glyceringuaiacol per day for 14 days
Number of subjects: 23
Study 30855411 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture removal 6 weeks postoperatively
Number of subjects: 82
Study 30855411 — intervention group
Group type: COMPARATOR
Intervention: Suture left in place (Control)
Number of subjects: 82
Study 29912935 — intervention group
Group type: EXPERIMENTAL
Intervention: Egocentric network support for physical activity (PA)
Number of subjects: 102
Study 29912935 — intervention group
Group type: EXPERIMENTAL
Intervention: Network size, familial ties, contact frequency
Number of subjects: 102
Study 29912935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego-alter dissimilarities in age and running, similarities in walking
Number of subjects: 102
Study 26813467 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodigest® (ginger and artichoke extract)
Number of subjects: 11
Study 26813467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 26813467 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodigest® (two capsules)
Number of subjects: 11
Study 23751914 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma neurofeedback
Number of subjects: 20
Study 23751914 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta neurofeedback
Number of subjects: 20
Study 18508296 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of peginterferon‐alpha‐2a (180 microg/week) and ribavirin (1000‐1200 mg/day)
Number of subjects: 200
Study 18508296 — intervention group
Group type: COMPARATOR
Intervention: 48 weeks of peginterferon‐alpha‐2a (180 microg/week) and ribavirin (1000‐1200 mg/day)
Number of subjects: 200
Study 15173679 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 15173679 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 0
Study 15173679 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0
Study 15173679 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0
Study 11318060 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-paced condition
Number of subjects: 0
Study 11318060 — intervention group
Group type: COMPARATOR
Intervention: Computer-paced condition
Number of subjects: 0
Study 11318060 — intervention group
Group type: EXPERIMENTAL
Intervention: Response deadline imposed in Experiment 3
Number of subjects: 0
Study 9088894 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 IE per kg body weight regular insulin (insulin induced hypoglycemia)
Number of subjects: 15
Study 9088894 — intervention group
Group type: COMPARATOR
Intervention: 1 ml 0.9% sodium chloride (placebo)
Number of subjects: 15
Study 9088894 — intervention group
Group type: COMPARATOR
Intervention: 0.1 IE per kg body weight regular insulin plus glucose 10% (euglycemic hyperinsulinemic glucose clamp)
Number of subjects: 15
Study 8192109 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (HDD) for 48 hours followed by intermediate-dose dexamethasone (IDD)
Number of subjects: 12
Study 8192109 — intervention group
Group type: COMPARATOR
Intervention: High-dose dexamethasone (HDD) followed by no steroids with cranial radiotherapy
Number of subjects: 12
Study 2855297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms per treatment, intranasally, three times daily for 5 days)
Number of subjects: 63
Study 2855297 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 63
Study 2855297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 63
Study 11468426 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T monotherapy for 8 weeks
Number of subjects: 31
Study 31254201 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational arm (66.7% of deaths occurred here)
Number of subjects: 23387
Study 31254201 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-taxane-based chemotherapy (51.1% of deaths occurred here)
Number of subjects: 23387
Study 31254201 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 23387
Study 29606226 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Health smartphone application with daily surveys on cravings, affects, triggers, responses to triggers, and social contexts.
Number of subjects: 75
Study 29606226 — intervention group
Group type: COMPARATOR
Intervention: Text messages from S-Health (e.g., HIV prevention and other educational materials).
Number of subjects: 75
Study 27352175 — intervention group
Group type: EXPERIMENTAL
Intervention: C18 (18 mmol/l citrate solution)
Number of subjects: 48
Study 27352175 — intervention group
Group type: COMPARATOR
Intervention: C15 (15 mmol/l citrate solution)
Number of subjects: 48
Study 25001621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil administered intraoperatively and hydromorphone dosed postoperatively via target-controlled infusion (TCI) and patient-controlled analgesia (PCA) until 8 a.m. on the first postoperative day.
Number of subjects: 50
Study 25001621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 50
Study 25001621 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 50
Study 22157844 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) consisting of four 5 min cycles of lower limb ischaemia and reperfusion
Number of subjects: 55
Study 22157844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RIPC)
Number of subjects: 55
Study 19875173 — intervention group
Group type: COMPARATOR
Intervention: Everting sutures (ES) alone
Number of subjects: 63
Study 19875173 — intervention group
Group type: EXPERIMENTAL
Intervention: Everting sutures with a lateral tarsal strip (ES+LTS)
Number of subjects: 63
Study 17291336 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiocolloid and blue dye technique for SLN biopsy
Number of subjects: 371
Study 16158800 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement and short-term usage of antimicrobial agents
Number of subjects: 0
Study 16158800 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole dispensed after the first and second annual examinations
Number of subjects: 0
Study 16158800 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 12008938 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with melagatran and ximelagatran or dalteparin (exact dosage not specified)
Number of subjects: 1600
Study 10482198 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (Herceptin) alone
Number of subjects: 0
Study 10482198 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 0
Study 10482198 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 7568633 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg EtOH
Number of subjects: 3
Study 7568633 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg EtOH
Number of subjects: 3
Study 7568633 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg EtOH
Number of subjects: 3
Study 7568633 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g/kg EtOH
Number of subjects: 3
Study 7568633 — intervention group
Group type: COMPARATOR
Intervention: Baseline performance
Number of subjects: 3
Study 2332569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipivefrin 0.1% eye drops
Number of subjects: 5
Study 2332569 — intervention group
Group type: COMPARATOR
Intervention: Patch testing with individual components of Propine
Number of subjects: 5
Study 6795164 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 0
Study 6795164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31651944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-extracorporeal circulation (MECC)
Number of subjects: 230
Study 31651944 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting (OPCABG)
Number of subjects: 230
Study 30308523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral suprazygomatic maxillary nerve blocks
Number of subjects: 114
Study 30308523 — intervention group
Group type: COMPARATOR
Intervention: Bilateral infraorbital nerve blocks and bilateral greater and lesser palatine nerve blocks and nasopalatine nerve block
Number of subjects: 114
Study 28187044 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy (MIE)
Number of subjects: 115
Study 28187044 — intervention group
Group type: COMPARATOR
Intervention: Open esophagectomy
Number of subjects: 115
Study 26246458 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day plus saxagliptin and metformin
Number of subjects: 0
Study 26246458 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus saxagliptin and metformin
Number of subjects: 0
Study 26246458 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 0
Study 26246458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25138183 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 240
Study 22935227 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella vaccine in SLE patients (28 vaccinated)
Number of subjects: 54
Study 22935227 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (28 vaccinated)
Number of subjects: 54
Study 22935227 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated SLE group (26 unvaccinated)
Number of subjects: 54
Study 19899831 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 107
Study 19899831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 17767456 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 15220251 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg/day)
Number of subjects: 40
Study 11242149 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) 300 mg twice a day until labour, 600 mg at the beginning of labour, and 300 mg twice a day for 7 days post-partum (n = 23)
Number of subjects: 172
Study 11242149 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 172
Study 11242149 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) (n = 47)
Number of subjects: 172
Study 11242149 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 70)
Number of subjects: 172
Study 9586595 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐adrenoceptor‐blockers
Number of subjects: 0
Study 9586595 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐α‐reductase inhibitors
Number of subjects: 0
Study 9586595 — intervention group
Group type: EXPERIMENTAL
Intervention: More uroselective α‐blockers
Number of subjects: 0
Study 8147676 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (specific drugs not mentioned)
Number of subjects: 0
Study 8147676 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 8147676 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive agents (general)
Number of subjects: 0
Study 8147676 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires for assessing sexual dysfunction
Number of subjects: 0
Study 8147676 — intervention group
Group type: EXPERIMENTAL
Intervention: Research protocols using a double-blind, placebo-controlled design
Number of subjects: 0
Study 2703283 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed 'unisex' regression equations for pulmonary function prediction
Number of subjects: 374
Study 2703283 — intervention group
Group type: COMPARATOR
Intervention: Commonly recommended pulmonary function prediction equations
Number of subjects: 374
Study 31183902 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital workflow (test group)
Number of subjects: 31
Study 31183902 — intervention group
Group type: COMPARATOR
Intervention: Conventional workflow (control group)
Number of subjects: 31
Study 31183902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both workflows
Number of subjects: 31
Study 28581693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pink abutment
Number of subjects: 40
Study 28581693 — intervention group
Group type: COMPARATOR
Intervention: Gray abutment
Number of subjects: 40
Study 25224097 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation
Number of subjects: 196
Study 25224097 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (men only)
Number of subjects: 196
Study 25224097 — intervention group
Group type: COMPARATOR
Intervention: Usual care (men only)
Number of subjects: 196
Study 23954313 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF‐R1 antagonist (GW876008) 20 mg or 200 mg
Number of subjects: 26
Study 23954313 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF‐R1 antagonist (GW876008)
Number of subjects: 26
Study 23954313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21476113 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental inspired oxygen for the first 2 days after surgery
Number of subjects: 274
Study 21476113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplemental oxygen)
Number of subjects: 274
Study 21476113 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental inspired oxygen for the first 2 days after surgery (isolated groin incisions)
Number of subjects: 274
Study 21476113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplemental oxygen, isolated groin incisions)
Number of subjects: 274
Study 18057049 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical pleural abrasion (group A)
Number of subjects: 208
Study 18057049 — intervention group
Group type: COMPARATOR
Intervention: Apical pleurectomy (group B)
Number of subjects: 208
Study 16542503 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate (1,600 mg/day)
Number of subjects: 1069
Study 12674267 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal cognitive problem-solving
Number of subjects: 39
Study 12674267 — intervention group
Group type: COMPARATOR
Intervention: Language workshop
Number of subjects: 39
Study 10741706 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg/m2 ATRA once daily
Number of subjects: 21
Study 10741706 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg/m2 ATRA once daily
Number of subjects: 21
Study 10741706 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/m2 ATRA once daily
Number of subjects: 21
Study 10741706 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/m2/day ATRA every 8 h
Number of subjects: 21
Study 10741706 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA pharmacokinetics
Number of subjects: 21
Study 9093241 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8463519 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% protein (61 g protein/L; n = 15)
Number of subjects: 28
Study 8463519 — intervention group
Group type: COMPARATOR
Intervention: 14% protein (37 g protein/L; n = 13)
Number of subjects: 28
Study 3768576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (one or more of a selection of individually tailored, cognitive‐behavioural therapies lasting an average of 9.1 sessions)
Number of subjects: 37
Study 3768576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 37
Study 3768576 — intervention group
Group type: COMPARATOR
Intervention: Minimal treatment (three or four sessions' assessment and advice)
Number of subjects: 37
Study 30298859 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23% acidulated phosphate fluoride gel (APG)
Number of subjects: 25
Study 30298859 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% neutral fluoride gel (NFG)
Number of subjects: 25
Study 30298859 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23% acidulated fluoride mousse (AFM)
Number of subjects: 25
Study 30298859 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (5% Duraphat, DFV)
Number of subjects: 25
Study 30298859 — intervention group
Group type: COMPARATOR
Intervention: Untreated (C control)
Number of subjects: 25
Study 28341592 — intervention group
Group type: EXPERIMENTAL
Intervention: AlloMax
Number of subjects: 30
Study 28341592 — intervention group
Group type: COMPARATOR
Intervention: AlloDerm RTU
Number of subjects: 30
Study 28341592 — intervention group
Group type: EXPERIMENTAL
Intervention: AlloDerm RTU and AlloMax
Number of subjects: 30
Study 26297933 — intervention group
Group type: EXPERIMENTAL
Intervention: Integra Dermal Regeneration Template (IDRT); n = 154
Number of subjects: 307
Study 26297933 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride gel (control); n = 153
Number of subjects: 307
Study 23632737 — intervention group
Group type: EXPERIMENTAL
Intervention: DSS Group
Number of subjects: 150
Study 23632737 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 150
Study 23661841 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined supplement of 40 mg zinc as zinc gluconate and 40 mg iron as ferrous sulphate
Number of subjects: 100